Director, US Strategy & Business Planning; Biosimilars

Director, US Strategy & Business Planning (Biosimilars)

Join to apply for the Director, US Strategy & Business Planning (Biosimilars) role at Fresenius Kabi USA.

Fresenius Kabi is hiring a Director, US Strategy & Business Planning. The selected candidate should have an excellent working knowledge and understanding of the biologics / biosimilars market including oncology and immunology categories. The individual will lead and assist in robust competitive analysis, including considerations of current and new competition, from biosimilars, originators, new treatment classes (raising the standard of treatment), as well as evolving access related policies that impact the market size for FK’s portfolio and potential sales.

The individual will lead in analytics related to biopharma marketing and sales segmentations, CRM integration and enhancements, digital capabilities. This individual will manage all databases of US biopharma portfolio as well as manage complex technical financial solutions to support strategic decision customer segmentation. The incumbent is expected to work with cross-functional teams across Global Marketing, Market Access, Sales, Medical Affairs, Finance, and IT.

Salary Range: $190,000 - $210,000 per year

Position is eligible to participate in a bonus plan with a target of 16% of the base salary. Position is also eligible to participate in our medium-term incentive plan. Final pay determinations will depend on various factors, including, but not limited to experience level, education, knowledge, skills, and abilities. Our benefits and programs are comprehensive and thoughtfully crafted to ensure our colleagues live healthy lives and have support when it matters most.

• Lead competitive analysis and readiness activities, including but not limited to monitoring current and future biosimilar / originator competition, driving deep insights on how the treatment paradigms are changing across different TAs.
• Ensure best practices in all connectivity between the existing biopharma team platform like Veeva CRM, CDP, Optimizer, Form Track, IC360 and Qlik. Identify gaps and recommend further enhancements.
• Manage and develop the strategy on all 3rd party data subscriptions (DDD, One Key, LAAD, MMIT, etc) as well as internal data integration from SAP and Model N, ensuring data integrity within the CDP and Qlik.
• Collaborate with Sales and Marketing teams on establishing and enhancing the launch performance trackers with the focus on pre-launch and post-launch metrics, including call planning, call tracking, adherence to call plan, market share metrics, relative performance to existing and new biosimilars.
• Manage Launch Readiness for biosimilars from foundational market understanding through key activity identification, competitive analysis, short-term and long-term tiering decisions relating to sales design, and tactic selection.
• Lead the establishing of a robust forecasts and CMS ASP analytical process/tool for each Fresenius Kabi biopharma asset based on existing and future contracts.
• Manage the establishment of Biopharma best practices in all analytical tools and financial models to be utilized by the Biopharma team, provide technical and training support.
• Manage all FC/MTS/BUD cycles, provide all internal and external data necessary to ensure cross functional alignment and timely delivery of presentations to senior management.

• Lead / assist in putting together high-quality presentations for senior leadership.
• Effectively communicate relevant project information to superiors including executive staff.
• Deliver informative and well-organized presentations.
• Drive to timely decisions as warranted.
• Resolve and/or escalates issues in a timely fashion.
• Understand how to communicate difficult/sensitive information tactfully.

• Possess an understanding in the functional areas associated with any given initiative.
• Possess a thorough understanding of the company’s capabilities.
• Maintain awareness of new and emerging formulations by branded/biopharma competitors, manufacturing and packaging technologies.
• Remain on the forefront of emerging industry practices.